.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Federal Trade Commission
UBS
Julphar
AstraZeneca
QuintilesIMS
Farmers Insurance
Colorcon
Novartis
Mallinckrodt

Generated: November 23, 2017

DrugPatentWatch Database Preview

EVAMIST Drug Profile

« Back to Dashboard

What is the patent landscape for Evamist, and what generic Evamist alternatives are available?

Evamist is a drug marketed by Perrigo Pharma Intl and is included in one NDA. There are four patents protecting this drug.

This drug has fifty-four patent family members in seventeen countries and thirty-six supplementary protection certificates in eleven countries.

The generic ingredient in EVAMIST is estradiol. There are seventy-five drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the estradiol profile page.

Pharmacology for EVAMIST

Ingredient-typeEstradiol Congeners
Drug ClassEstrogen
Mechanism of ActionEstrogen Receptor Agonists

Medical Subject Heading (MeSH) Categories for EVAMIST

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Perrigo Pharma Intl
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Perrigo Pharma Intl
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Perrigo Pharma Intl
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Perrigo Pharma Intl
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: EVAMIST

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Perrigo Pharma Intl
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007► Subscribe► Subscribe
Perrigo Pharma Intl
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007► Subscribe► Subscribe
Perrigo Pharma Intl
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: EVAMIST

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
► Subscribe
EVAMIST
► Subscribe

Non-Orange Book Patents for Tradename: EVAMIST

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,916,486 Transdermal delivery of analgesics► Subscribe
6,964,777 Transdermal delivery of antianxiety agents► Subscribe
6,998,138Topical delivery of anti-alopecia agents► Subscribe
7,438,203Dermal penetration enhancers and drug delivery systems involving same► Subscribe
7,387,789Transdermal delivery of non-steroidal anti-inflammatory drugs► Subscribe
8,071,075Dermal penetration enhancers and drug delivery systems involving the same► Subscribe
7,094,422Topical delivery of antifungal agents► Subscribe
6,929,801 Transdermal delivery of antiparkinson agents► Subscribe
6,916,487 Transdermal delivery of antiemetics► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: EVAMIST

Country Document Number Estimated Expiration
Germany122012000020► Subscribe
Luxembourg91973► Subscribe
Japan4011480► Subscribe
Spain2348313► Subscribe
Spain2314538► Subscribe
European Patent Office1345549► Subscribe
Spain2262173► Subscribe
Denmark0901368► Subscribe
Denmark1674068► Subscribe
Australia1713497► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: EVAMIST

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2012 00010Denmark► Subscribe
2006 00038Denmark► SubscribePRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
C0005Belgium► SubscribePRODUCT NAME: ESTRADIOL HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: 298 IS 190 F 15 19960806; FIRST REGISTRATION: GB PL/0053/0241 19950711
C0018France► SubscribePRODUCT NAME: ESTRADIOL VALERATE; DIENOGEST; NAT. REGISTRATION NO/DATE: NL35170 20081210; FIRST REGISTRATION: BE327792 20081103
971Luxembourg► Subscribe91971, EXPIRES: 20220219
972Luxembourg► Subscribe91972, EXPIRES: 20220219
C0004Belgium► SubscribePRODUCT NAME: ESTRADIOL, HEMIHYDRATE, NORETHISTERONE, ACETATE; NAT. REGISTRATION NO/DATE: NL 23753 19981210; FIRST REGISTRATION: SE - 14 007 19980306
2012 00012Denmark► Subscribe
C0001France► SubscribePRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
00522Netherlands► SubscribePRODUCT NAME: FENTANYL EN DOSERINGSAPPLICATOR; REG. NO/DATE: EU/2/11/127/001 20111006
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
US Department of Justice
Covington
McKinsey
Dow
McKesson
Argus Health
Cerilliant
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot